Aurobindo Pharma shares fall 3% after Q2 earnings

New Delhi: Shares of Aurobindo Pharma Tuesday fell almost 3 per cent after the company reported 21.70 per cent dip in consolidated net profit for the quarter ended September 30, 2018. The stock went down 2.96 per cent to end at Rs 774.70 on BSE. During the day, it declined 4.76 per cent to Rs 760.25.

On NSE, shares of the company dropped 2.63 per cent to close at Rs 775.

Aurobindo Pharma Monday reported 21.70 per cent dip in consolidated net profit to Rs 611.44 crore for the September quarter, mainly on account of rise in expenses.

The company had posted a net profit of Rs 780.97 crore in the year-ago period, Aurobindo Pharma said in a BSE filing.

Consolidated total revenue from operations stood at Rs 4,751.40 crore for the quarter under review. It was Rs 4,435.89 crore in the same period last year.

Total expenses stood at Rs 3,964.20 crore for the reported quarter. It was Rs 3,468.36 crore during the same period of 2017-18.

  • Related Posts

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    New Delhi — In a significant move to bring greater transparency and accountability in healthcare delivery, the Centre has directed all states and Union Territories to tighten regulatory oversight within…

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid